13F Holdings
中文EN

SRPT Sarepta Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 873303 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-18.9%
TTM net income YoY19.4%
TTM EPS YoY19.9%
Revenue 3-yr CAGR21.0%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-2.5%
Net margin-5.9%
FCF margin9.0%
EBITDA margin-0.9%

Returns

ROE-7.6%
ROA-3.4%
ROIC (approx.)-2.5%
Asset turnover0.59x

Leverage & solvency

Liabilities / assets51.7%
Debt / equity0.66x
Current ratio3.46x
Interest coverage0.62x

Cash quality & payout

Operating cash flow / net income-1.62x
Accruals ratio-9.0%
Payout ratio—
Capex / revenue0.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$2.20B$1.90B$1.24B$933.01M$701.89M
Cost of revenue$25.50M————
Gross profit$2.17B————
R&D expense$1.52B$804.52M$877.39M$877.09M$771.18M
SG&A expense$491.72M$557.87M$481.87M$451.42M$282.66M
Operating income-$699.78M$218.08M-$267.82M-$536.20M-$459.71M
Interest expense-$38.14M-$18.39M-$22.01M-$53.25M$63.52M
Pretax income-$702.23M$260.77M-$520.10M-$689.96M-$418.95M
Income tax$11.19M$25.54M$15.88M$13.53M-$168,000
Net income-$713.41M$235.24M-$535.98M-$703.49M-$418.78M
EBITDA-$655.26M$255.81M-$223.43M-$494.34M-$421.69M
EPS (basic)-7.132.47-5.80-8.03-5.15
EPS (diluted)-7.132.34-5.80-8.03-5.15
Weighted avg. shares (diluted)100.12M107.88M92.40M87.56M81.26M
Balance sheet
Cash & equivalents$801.28M$1.12B$428.43M$966.78M$2.12B
Short-term investments$138.37M$251.78M$1.25B$1.02B$0
Receivables$398.23M$601.99M$400.33M$214.63M$152.99M
Inventory$914.74M$749.96M$322.86M$203.97M$186.21M
Current assets$2.54B$3.07B$2.58B$2.56B$2.60B
PP&E, net$345.12M$340.34M$227.15M$180.04M$191.16M
Intangibles$28.95M$26.89M$29.62M$7.58M$14.24M
Total assets$3.35B$3.96B$3.26B$3.13B$3.15B
Current liabilities$1.10B$731.68M$653.66M$619.60M$452.73M
Short-term debt$0$0$105.48M$0—
Long-term debt$828.97M$1.14B$1.24B$1.54B$563.67M
Total debt$828.97M$1.14B$1.34B$1.54B$563.67M
Total liabilities$2.21B$2.44B$2.41B$2.74B$2.22B
Shareholders' equity$1.14B$1.53B$859.34M$384.95M$928.01M
Net debt$27.69M$18.54M$915.05M$577.51M-$1.55B
Shares outstanding104.96M96.90M93.73M87.95M87.13M
Cash flow statement
Operating cash flow-$205.48M-$205.79M-$500.99M-$325.35M-$443.17M
Capital expenditure$101.97M$136.96M$76.11M$30.82M$38.49M
Free cash flow-$307.45M-$342.74M-$577.10M-$356.17M-$481.66M
Investing cash flow$69.64M$755.56M-$165.80M-$1.05B$495.41M
Financing cash flow-$168.34M$124.81M$125.00M$232.51M$561.57M
Depreciation & amortization$44.52M$37.72M$44.40M$41.86M$38.02M
Stock-based compensation$123.40M$184.30M$182.51M$233.02M$113.94M
Share buybacks$25.01M$0$0——

Free plan shows the latest 5 periods; Pro shows all 17 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.